These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 25711949)
1. The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology. Kenter MJ; Cohen AF Br J Clin Pharmacol; 2015 Apr; 79(4):545-7. PubMed ID: 25711949 [No Abstract] [Full Text] [Related]
3. CD28 superagonists: what makes the difference in humans? Schraven B; Kalinke U Immunity; 2008 May; 28(5):591-5. PubMed ID: 18482560 [TBL] [Abstract][Full Text] [Related]
4. After TGN1412: recent developments in cytokine release assays. Stebbings R; Eastwood D; Poole S; Thorpe R J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038 [TBL] [Abstract][Full Text] [Related]
5. Primate testing of TGN1412: right target, wrong cell. Pallardy M; Hünig T Br J Pharmacol; 2010 Oct; 161(3):509-11. PubMed ID: 20880391 [TBL] [Abstract][Full Text] [Related]
10. Benefit and risk assessment in drug development and utilization: a role for clinical pharmacology. Honig P Clin Pharmacol Ther; 2007 Aug; 82(2):109-12. PubMed ID: 17632530 [No Abstract] [Full Text] [Related]
12. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Hünig T Nat Rev Immunol; 2012 Apr; 12(5):317-8. PubMed ID: 22487653 [TBL] [Abstract][Full Text] [Related]
13. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661 [TBL] [Abstract][Full Text] [Related]
14. Lessons from TGN-1412 - the impact on phase I clinical trials. Weerasekera N; Hudson I IDrugs; 2007 Apr; 10(4):230-2. PubMed ID: 17390240 [No Abstract] [Full Text] [Related]
15. Quantitative Systems Pharmacology: A Case for Disease Models. Musante CJ; Ramanujan S; Schmidt BJ; Ghobrial OG; Lu J; Heatherington AC Clin Pharmacol Ther; 2017 Jan; 101(1):24-27. PubMed ID: 27709613 [TBL] [Abstract][Full Text] [Related]
16. Qualitative pharmacology in a quantitative world: diminishing value in the drug discovery process. Williams M Curr Opin Pharmacol; 2011 Oct; 11(5):496-500. PubMed ID: 21531622 [TBL] [Abstract][Full Text] [Related]
17. The extinction of drugs for clinical research: Can the ECNP medicines chest save them? Nutt D; Kilpatrick G; Hayes A Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534 [No Abstract] [Full Text] [Related]
18. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. Hünig T FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544 [TBL] [Abstract][Full Text] [Related]
19. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation. Tabrizi M; Neupane D; Elie SE; Shankaran H; Juan V; Zhang S; Hseih S; Fayadat-Dilman L; Zhang D; Song Y; Ganti V; Judo M; Spellman D; Seghezzi W; Escandon E AAPS J; 2019 Mar; 21(3):39. PubMed ID: 30868312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]